Mercedes Gonzalez-juarrero

List of Publications by Year
in descending order

53 papers	3,101 citations	218677 26 h-index	168389 53 g-index
54 all docs	54 docs citations	54 times ranked	4212 citing authors

#	Article	IF	Citations
1	In Vivo IL-10 Production Reactivates Chronic Pulmonary Tuberculosis in C57BL/6 Mice. Journal of Immunology, 2002, 169, 6343-6351.	0.8	243
2	Interleukin-10 Promotes Mycobacterium tuberculosis Disease Progression in CBA/J Mice. Journal of Immunology, 2008, 181, 5545-5550.	0.8	198
3	Dynamics of Macrophage Cell Populations During Murine Pulmonary Tuberculosis. Journal of Immunology, 2003, 171, 3128-3135.	0.8	186
4	Temporal and Spatial Arrangement of Lymphocytes within Lung Granulomas Induced by Aerosol Infection withMycobacterium tuberculosis. Infection and Immunity, 2001, 69, 1722-1728.	2.2	181
5	Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. Journal of Leukocyte Biology, 2005, 77, 914-922.	3.3	174
6	Localized Immunosuppressive Environment in the Foreign Body Response to Implanted Biomaterials. American Journal of Pathology, 2009, 175, 161-170.	3.8	161
7	Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nature Medicine, 2014, 20, 152-158.	30.7	160
8	Characterization of Murine Lung Dendritic Cells Infected with Mycobacterium tuberculosis. Infection and Immunity, 2001, 69, 1127-1133.	2.2	147
9	Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. DMM Disease Models and Mechanisms, 2015, 8, 591-602.	2.4	127
10	Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. Journal of Leukocyte Biology, 2010, 88, 159-168.	3.3	101
11	Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrobial Agents and Chemotherapy, 2016, 60, 5198-5207.	3.2	99
12	Foamy Macrophages within Lung Granulomas of Mice Infected withMycobacterium tuberculosisExpress Molecules Characteristic of Dendritic Cells and Antiapoptotic Markers of the TNF Receptor-Associated Factor Family. Journal of Immunology, 2005, 175, 3873-3881.	0.8	91
13	Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis, 2009, 89, 149-157.	1.9	89
14	Long-term Survival and Virulence of Mycobacterium leprae in Amoebal Cysts. PLoS Neglected Tropical Diseases, 2014, 8, e3405.	3.0	78
15	Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. ACS Infectious Diseases, 2019, 5, 1001-1012.	3.8	74
16	Partial Saturation of Menaquinone in Mycobacterium tuberculosis: Function and Essentiality of a Novel Reductase, MenJ. ACS Central Science, 2015, 1, 292-302.	11.3	71
17	Reduced in vitro immune response on titania nanotube arrays compared to titanium surface. Biomaterials Science, 2013, 1, 322-332.	5.4	66
18	Evidence of zoonotic leprosy in ParÃ¡, Brazilian Amazon, and risks associated with human contact or consumption of armadillos. PLoS Neglected Tropical Diseases, 2018, 12, e0006532.	3.0	65

#	Article	IF	Citations
19	Intrapulmonary Delivery of XCL1-Targeting Small Interfering RNA in Mice Chronically Infected withMycobacterium tuberculosis. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 136-145.	2.9	60
20	Relative Levels of M-CSF and GM-CSF Influence the Specific Generation of Macrophage Populations during Infection withMycobacterium tuberculosis. Journal of Immunology, 2008, 180, 4892-4900.	0.8	57
21	Local pulmonary immunotherapy with siRNA targeting TGFÎ²1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis, 2011, 91, 98-106.	1.9	50
22	GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy, 2014, 69, 1057-1064.	3.0	49
23	Enhanced Macrophage Activity in Granulomatous Lesions of Immune Mice Challenged with Mycobacterium tuberculosis. Journal of Immunology, 2006, 176, 4931-4939.	0.8	40
24	Factors Associated with Severe Granulomatous Pneumonia in Mycobacterium tuberculosis-Infected Mice Vaccinated Therapeutically with hsp65 DNA. Infection and Immunity, 2005, 73, 5189-5193.	2.2	36
25	Evaluation of shedding, tissue burdens, and humoral immune response in goats after experimental challenge with the virulent Brucella melitensis strain 16M and the reduced virulence vaccine strain Rev. 1. PLoS ONE, 2017, 12, e0185823.	2.5	36
26	Immune Response toMycobacterium tuberculosisand Identification of Molecular Markers of Disease. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 398-409.	2.9	34
27	Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent. Frontiers in Microbiology, 2018, 9, 2231.	3.5	28
28	Florid pulmonary inflammatory responses in mice vaccinated with Antigen-85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis. Cellular Immunology, 2002, 220, 13-19.	3.0	27
29	Yersinia pestisSurvival and Replication in Potential Ameba Reservoir. Emerging Infectious Diseases, 2018, 24, 294-302.	4.3	27
30	Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells. Tuberculosis, 2011, 91, 86-92.	1.9	25
31	Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery. Antimicrobial Agents and Chemotherapy, 2012, 56, 3957-3959.	3.2	25
32	Host Directed Therapy for Chronic Tuberculosis via Intrapulmonary Delivery of Aerosolized Peptide Inhibitors Targeting the IL-10-STAT3 Pathway. Scientific Reports, 2018, 8, 16610.	3.3	25
33	The minipig as an animal model to study Mycobacterium tuberculosis infection and natural transmission. Tuberculosis, 2017, 106, 91-98.	1.9	23
34	Experimental aerosol Mycobacterium bovis model of infection in goats. Tuberculosis, 2013, 93, 558-564.	1.9	22
35	Interactions of free-living amoebae with rice bacterial pathogens Xanthomonas oryzae pathovars oryzae and oryzicola. PLoS ONE, 2018, 13, e0202941.	2.5	22
36	Mycobacterium bovis hosted by freeâ€livingâ€amoebae permits their longâ€term persistence survival outside of host mammalian cells and remain capable of transmitting disease to mice. Environmental Microbiology, 2017, 19, 4010-4021.	3.8	21

#	Article	IF	Citations
37	Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Advanced Drug Delivery Reviews, 2016, 102, 21-32.	13.7	20
38	Immunity to TB and targets for immunotherapy. Immunotherapy, 2012, 4, 187-199.	2.0	19
39	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharmaceutical Research, 2019, 36, 136.	3.5	19
40	Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo. Journal of Antimicrobial Chemotherapy, 2020, 75, 1889-1894.	3.0	16
41	Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus. Science Translational Medicine, 2022, 14, eabj3860.	12.4	15
42	Animal Models of M. tuberculosis Infection. Current Protocols in Microbiology, 2007, 7, Unit 10A.5.	6.5	11
43	Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication in vitro. Precision Nanomedicine, 2021, 4, 724-737.	0.8	11
44	Unique Features of Mycobacterium abscessus Biofilms Formed in Synthetic Cystic Fibrosis Medium. Frontiers in Microbiology, 2021, 12, 743126.	3.5	11
45	Cell mediated immune response in goats after experimental challenge with the virulent Brucella melitensis strain 16M and the reduced virulence strain Rev. 1. Veterinary Immunology and Immunopathology, 2018, 202, 74-84.	1.2	9
46	Minipigs as a neonatal animal model for tuberculosis vaccine efficacy testing. Veterinary Immunology and Immunopathology, 2019, 215, 109884.	1.2	9
47	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. Tuberculosis, 2019, 114, 119-122.	1.9	8
48	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS Infectious Diseases, 2021, 7, 2850-2863.	3.8	8
49	Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	7
50	Polar Lipids of Burkholderia pseudomallei Induce Different Host Immune Responses. PLoS ONE, 2013, 8, e80368.	2.5	7
51	Microhemorrhage is an early event in the pulmonary fibrotic disease of PECAM-1 deficient FVB/n mice. Experimental and Molecular Pathology, 2014, 97, 128-136.	2.1	6
52	Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis. Frontiers in Microbiology, 2018, 9, 1895.	3.5	5
53	Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. Tuberculosis, 2019, 117, 52-55.	1.9	2